Yaz/Yasmin, a brand of oral hormonal contraceptive containing drospirenone that may also be used to treat premenstrual dysphoric disorder (PMDD). Drospirenone is a synthetic progestin that is typically used in birth control.
However, Yaz/Yasmin use has been associated with deep vein thrombosis, stroke, and heart attacks. If you or a loved one is using Yaz/Yasmin, read on for facts about the product and the litigation surrounding it.
Facts about Yaz/Yasmin:
- There have been concerns rose regarding its safety and is thus not recommended as a first line agent.
- On September 26, 2011 the FDA announced that it has not yet reached a conclusion, but remains concerned, about the potential increased risk of blood clots with the use of drospirenone-containing birth control pills. Preliminary results of the FDA-funded study suggest an approximately 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing birth control pills compared to users of other hormonal contraceptives.
- Yaz/Yasmin appears to increase the risk of venous thromboembolism more than levonorgestrel.
- On October 8, 2009, Bayer disclosed that 129 lawsuits had been brought against them over the side effects and marketing of Yaz and Yasmin.
- In October 2010, a Case Management Order was established in the federal MDL, scheduling three Yaz and Yasmin bellwether trials, which are representative cases that will be used to gauge how juries will respond to testimony and evidence that is likely to be introduced throughout other cases in the litigation.
- As of early 2011, the Yaz and Yasmin litigation consisted of nearly 7,000 individual injury cases that have been filed in state and federal courts throughout the United States on behalf of women who have experienced serious and potentially life-threatening injuries.
- On October 27, 2011, the Food and Drug Administration issued a Drug Safety Communication informing healthcare professionals and the public that FDA is continuing its review of the potential increased risk of blood clots with the use of birth control pills containing drospirenone.
- On December 8, 2011, The Food and Drug Administration’s panel of experts voted 21-5 that labeling on the drugs made by Bayer is inadequate and needs more information about the potential risk of blood clots in the legs and lungs.
If you have used or are using the Yaz/Yasmin and have suffered a DVT, pulmonary embolism, stroke or heart attack, or you have lost a loved one for one of these reasons, find out how Johnson//Becker PLLC can help you. Fill out our case review form here on our website and submit it for a free consultation.